Abstract:2514 Background: Melanomas and lung cancers usually display a large burden of somatically mutated proteins, yet only a subset of individuals can be induced to mount a therapeutic immune response against tumours. Inherited mutations in immune regulatory genes may be one factor predisposing to a heightened immune response with addition of an immune stimulus. Methods: Germline whole genome sequencing (WGS) was performed in a patient with exceptional response (ExR) to targeted radiotherapy for metastatic melanoma (complete abscopal response). A target variant gene was identified, and interrogated within a prospectively recruited cohort of patients with ExR or non-response to anti-PD1 for non-small cell lung cancer (NSCLC). Results were experimentally tested in mice and validated in an independent mixed cancer clinical cohort. Results: Compound heterozygous variants in NOD2 were found within the patient with abscopal response (expected genotype frequency 1.3 in 10,000), whose cancer regression occurred concurrently with a flare of pre-existing Crohn’s colitis (a NOD2-associated condition). Patients treated with anti-PD1 for NSCLC were prospectively recruited (n=144). Individuals with ExR to PD1 were selected, defined by progression-free survival (PFS) ≥2 years and ≥1 CTCAE grade 2 or higher immune-related adverse event (n=40). Median follow-up was 41 months (median PFS not reached). Patients with best response of progressive disease were selected for comparison (n=18, median PFS 2.76m, 95% CI, 2.1-3.81). WGS from blood was analysed for all human NOD2 variants known to impair NOD2 signalling. Of ExR patients, 25% carried 1 or more functional NOD2 variants, totalling 11 of 80 alleles (13.8%); more than twice the expected allele frequency (6.58%, p=0.0199). Within non-responders, 1 patient carried a variant NOD2 allele (1 of 36 alleles, 2.78%). The association between NOD2 loss-of-function and heightened immune response to anti-PD1 was experimentally tested in Nod2-null C57BL/6J ( Nod2 fs ) mice. Nod2 fs mice transplanted with a syngeneic cell line and treated with anti-PD1 showed greater tumour response compared with Nod2 wild-type littermates (60-day OS 41.67% vs 0%, p<0.01). Flow cytometry of tumours showed greater proportion of (CD44 hi CD62L low ) CD8 + and CD4 + effector memory differentiated cells within Nod2 fs versus Nod2 wild-type animals (p<0.05). Results were validated within an independent clinical cohort (n=105). Overall response rate to PD1 in patients with mutant vs wild-type NOD2 was 50% versus 15% (p=0.03). Conclusions: These results provide four complementary lines of evidence that common inherited defects in the immune regulatory gene NOD2 promote exceptional immune response following acute triggers to control cancer. NOD2 may be a biomarker for treatment stratification or a therapeutic target to enhance anti-PD1 response.

Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation

NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion

MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer

Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway

Co-occurring alteration of NOTCH and DDR pathways serve as novel predictor to efficacious immunotherapy in NSCLC.

NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer

Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐PD‐1/PD‐L1 therapy

PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance.

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells

Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I

Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity

Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.

Human endogenous retroviruses as epigenetic therapeutic targets in TP53 -mutated diffuse large B-cell lymphoma